Named Patient Program

Named Patient Program

The Named Patient (NPP) gives access in their own country for patients and clinicians to market authorized medicines. The Patient must approve these pharmaceuticals under the NPP in at least one country. With quickly changing lifestyles and constantly growing stress levels, disease patterns have trended towards rarer and more uncommon diseases.

The named Patients Program is increasingly being focused on as patients and caregivers become more conscious about unlicensed medicines and utilize social media and the Internet more often to collect and communicate medical information.

The Named Patient (NPP) gives access in their own country for patients and clinicians to market authorized medicines.

Speciality Medicines has skilled staff and world-class infrastructure to source medicines worldwide under the Named Patient Program. These diseases necessitate unlicensed drugs, orphan drugs, or unique drugs, as defined by the World Health Organization (WHO). The market has an unmet need for such medications, which fills up right away. Speciality Medicines has taken the initiative to supply this "unmet requirement" in the Indian market as one of India's few GDP-approved distributors.

The Named Patient Program/Manage Access Program was created by the Indian government and governments of many other nations worldwide for patients who have exhausted their local treatment choices and require the most up-to-date medicines available in Europe and the United States.